Heron Therapeutics (FRA:AXD2) Float Percentage Of Total Shares Outstanding: 78.45% (As of Jun. 29, 2026)


FRA:AXD2 Heron Therapeutics Inc FRA:AXD2
49 GF Score
Price €0.35
GF Value €1.28
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Heron Therapeutics Float Percentage Of Total Shares Outstanding?

Heron Therapeutics FRA:AXD2 -6.21% 49 Float Percentage Of Total Shares Outstanding is 78.45% as of Jun. 29, 2026. GuruFocus rates FRA:AXD2 with a GF Score™ of 49/100 and a GF Value™ of €1.28 (Possible Value Trap). The stock has 4 warning signs investors should review.

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Heron Therapeutics's float shares is 148.48 Mil. Heron Therapeutics's total shares outstanding is 189.28 Mil. Heron Therapeutics's float percentage of total shares outstanding is 78.45%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Heron Therapeutics's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Heron Therapeutics's Institutional Ownership is 21.07%.

FRA:AXD2
49GF Score
Heron Therapeutics Inc FRA:AXD2
Float Percentage Of Total Shares Outstanding is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Heron Therapeutics Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Heron Therapeutics's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=148.48/189.28
=78.45%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Float Percentage Of Total Shares Outstanding of 78.45% mean?
Heron Therapeutics (FRA:AXD2) has a Float Percentage Of Total Shares Outstanding of 78.45% as of Jun. 29, 2026. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Heron Therapeutics and its competitors.
Is Heron Therapeutics' Float Percentage Of Total Shares Outstanding too high?
Heron Therapeutics' current Float Percentage Of Total Shares Outstanding is 78.45%. Overall, Heron Therapeutics has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Heron Therapeutics' Float Percentage Of Total Shares Outstanding compare to ENTX and OKYO?
Heron Therapeutics' Float Percentage Of Total Shares Outstanding of 78.45% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Float Percentage Of Total Shares Outstanding for a Biotechnology company?
A good Float Percentage Of Total Shares Outstanding depends on the Biotechnology industry context. However, Float Percentage Of Total Shares Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Float Percentage Of Total Shares Outstanding mean?
A high Float Percentage Of Total Shares Outstanding can signal that a stock is expensive relative to its fundamentals. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Heron Therapeutics and its competitors. Heron Therapeutics's current Float Percentage Of Total Shares Outstanding is 78.45%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Heron Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Heron Therapeutics (FRA:AXD2) is currently considered Possible Value Trap. The stock's GF Value™ is €1.28, compared to a current price of €0.35 — trading 72.4% below its estimated fair value. The current Float Percentage Of Total Shares Outstanding is 78.45%. Heron Therapeutics' overall GF Score™ is 49/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Float Percentage Of Total Shares Outstanding calculated?
Float Percentage Of Total Shares Outstanding is calculated from a company's financial statements. For Heron Therapeutics (FRA:AXD2), the current Float Percentage Of Total Shares Outstanding is 78.45% as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Heron Therapeutics (FRA:AXD2) Overvalued in 2026?

Based on GuruFocus' analysis, Heron Therapeutics stock appears to be undervalued. The current stock price of €0.35 is trading 72.4% below its estimated GF Value™ of €1.28. GuruFocus considers Heron Therapeutics to be Possible Value Trap.

Key valuation signals for FRA:AXD2:

  • Float Percentage Of Total Shares Outstanding: 78.45%
  • GF Value™: €1.28 vs. price of €0.35 (72.4% below fair value)
  • GF Score™: 49/100 with 4 warning signs

No single metric tells the full story. See the FRA:AXD2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Heron Therapeutics Business Description

Other Exchanges HRTX:USA0J4V:UKAXD2:Germany
Address 100 Regency Forect Drive, Suite 300, Cary, NC, USA, 27518
Heron Therapeutics Inc is a commercial-stage biotechnology company. The company is focused on improving the lives of patients by developing treatments and commercializing therapeutic solutions to address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.
49GF Score

Get the complete analysis for FRA:AXD2

Float Percentage Of Total Shares Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.35
Price
€1.28
GF Value